Sunshine Biopharma Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2011. The unaudited company describes itself as a development-stage pharmaceutical business focused on cancer drug research, development, and commercialization. It reported no revenue from inception through the period.
Financial results and position
| Metric | Six months ended June 30, 2011 | Comparable 2010 period |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expenses | $65,706 | $1,672,709 |
| Net loss | $65,706 | $1,672,709 |
| Basic loss per share | Less than $0.01 | $0.06 |
| Net cash used in operating activities | $61,150 | $95,825 |
For the three months ended June 30, 2011, the company reported expenses and net loss of $16,490, versus $1,588,060 in the 2010 quarter; revenue was zero in both periods. No gross margin was reported because there was no revenue.
At June 30, 2011, cash and cash equivalents were $101,241, prepaid expenses were $41,273, and total assets were $142,514. Total liabilities were zero, compared with $11,404 at December 31, 2010. Shareholders’ equity was $142,514. Investing and financing cash flows were each zero for the six-month period. The filing reports no debt balance.
Changes versus the prior period
Six-month expenses and net loss fell by $1,607,003 from 2010. Management attributes most of the reduction to the absence of a $1,574,500 stock-based consultant charge and a $50,000 intangible-asset write-down recorded in 2010, as well as lower professional fees. The 2011 period included $17,650 of research and development expense. Cash declined by $61,150 during the six months, from $162,391 at year-end 2010.
Business outlook, risks, and other notable items
- The lead candidate, Adva-27a (difluoro-etoposide), remained in preclinical development. The company said it planned to begin Phase I trials for breast cancer at Montreal’s Jewish General Hospital by mid-to-late 2012, subject to obtaining funding; it anticipated trial completion in 2013. These are plans, not assured milestones.
- A June 2011 agreement with the hospital contemplated Phase I trials. A research agreement with the Research Foundation of the State University of New York covered preclinical development and was dependent on funding. The filing said no definitive agreement existed to fund the project fully.
- Management estimated that approximately $7.5 million of debt and/or equity capital would be needed to implement its business plan. The company had not secured a funding commitment and warned that inability to raise funds could materially harm operations and its financial condition. It expected costs to rise as research and clinical work expanded.
- In July 2011, after quarter-end, the company reported an in-vitro study indicating Adva-27a clearance pathways independent of Cytochrome P450 activity. This was a preclinical laboratory finding, not evidence of clinical safety or efficacy.
- Potential compassionate-use marketing and related revenue were contingent on funding, successful Phase I trials, and regulatory approval. The filing gave no assurance these would occur.
- Management concluded disclosure controls were effective as of June 30, 2011 and reported no material change in internal control over financial reporting. No legal proceedings, defaults on senior securities, or unregistered equity sales were reported in the listed sections.
Important facts for investors to verify
- Whether the company raised sufficient financing, particularly in light of its stated $7.5 million capital need and limited cash balance.
- Whether the hospital and research arrangements were funded and whether clinical-trial milestones were subsequently achieved.
- What evidence supports Adva-27a’s preclinical claims and what additional safety, efficacy, and regulatory requirements remain.
- The filing contains inconsistencies to check against the underlying statements: MD&A describes 2011 license fees of $15,840, while the operations statement lists $15,119; MD&A compares operating cash use with a period ending March 31, 2010, while the cash-flow statement presents the six months ended June 30, 2010.